HRMY

Harmony Biosciences Holdings Inc

Add to Watchlist

Advanced Chart

34.190

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

34.545

Open

34.260

VWAP

34.13

Vol

413.41K

Mkt Cap

1.97B

Low

33.710

Amount

14.11M

EV/EBITDA(TTM)

6.40

Total Shares

56.79M

1.57B

EV/OCF(TTM)

6.07

P/S(TTM)

2.58

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

220.49M

+18.52%

235.71M

+17.11%

215.96M

+16.9%

Estimates Revision

The market is revising Upward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by 0.41%.

Revenue Estimates for FY2025

Revise Upward

+0.41%

In Past 3 Month

Stock Price

Go Up

+0.41%

In Past 3 Month

8 Analyst Rating

44.43% Upside

Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 49.38 USD with a low forecast of 31.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

1 Sell

Moderate Buy

44.43% Upside

Current: 34.190

Low

31.00

Averages

49.38

High

70.00

44.43% Upside

Current: 34.190

Low

31.00

Averages

49.38

High

70.00

Truist

initiated

$48

2025-07-21

Reason

Truist

Price Target

$48

2025-07-21

initiated

Reason

Truist initiated coverage of Harmony Biosciences with a Buy rating and $48 price target. Truist sees unrealized value in the stock for the base business alone, and expects the Wakix narcolepsy franchise growth to continue until its loss of exclusivity, generating more than $1B by 2027, the analyst tells investors in a research note. The firm sees several potential future growth levers with Wakix life-cycle management and new formulations, and the expanding clinical pipeline.

Goldman Sachs

Corinne Johnson

Neutral

maintain

$33

2025-07-10

Reason

Goldman Sachs

Corinne Johnson

Price Target

$33

2025-07-10

maintain

Neutral

Reason

Goldman Sachs analyst Corinne Johnson resumed coverage of Harmony Biosciences with a Neutral rating and $33 price target. The firm expects the outlook for the Wakix franchise to remain the driver of the shares.

Deutsche Bank

Buy

maintain

$54 -> $55

2025-07-10

Reason

Deutsche Bank

Price Target

$54 -> $55

2025-07-10

maintain

Buy

Reason

Deutsche Bank raised the firm's price target on Harmony Biosciences to $55 from $54 and keeps a Buy rating on the shares. The firm says the company has a key clinical catalyst this quarter with readout of the Phase 3 RECONNECT trial in Fragile X syndrome. The data could materially drive shares if positive and "presents asymmetric risk-reward to the upside," the analyst tells investors in a research note.

Oppenheimer

Outperform

initiated

$61

2025-06-02

Reason

Oppenheimer

Price Target

$61

2025-06-02

initiated

Outperform

Reason

Oppenheimer assumed coverage of Harmony Biosciences with an Outperform rating and $61 price target. The firm notes Harmony BioSciences' solid Q1 results featured $184.7M in revenues, beating both our/consensus $178.5M/$182.3M estimates. Despite typical Q1 seasonal dynamics, Oppenheimer is encouraged by WAKIX's ongoing momentum with average number of patients growing to about 7,200, and continuing adoption among prescribers. Management expects continued patient growth through the year to support its reiterated FY25 revenue guidance of $820M-$860M. The firm is also encouraged by progress in the Pitolisant-HD and Pitolisant-GR programs. In terms of the pipeline, while not currently included in its valuation, Oppenheimer sees attractive upside potential in Harmony's neurobehavioral and epilepsy pipelines. Phase 3 FXS top-line results remain on track for Q3 2025.

Mizuho

Outperform

maintain

$44 -> $48

2025-05-15

Reason

Mizuho

Price Target

$44 -> $48

2025-05-15

maintain

Outperform

Reason

Mizuho raised the firm's price target on Harmony Biosciences to $48 from $44 and keeps an Outperform rating on the shares post the Q1 report. The firm left the quarter "pleased," given a Wakix revenue beat and no negative pipeline surprises, with lead asset Wakix "steadily rumbling toward" becoming a $1B product. Miuzho is most focused on Harmony's pipeline, which features six programs that are expected to be in Phase 3 by the end of 2025.

Needham

Ami Fadia

Strong Buy

Reiterates

$50

2025-04-10

Reason

Needham

Ami Fadia

Price Target

$50

2025-04-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY.O) is 10.34, compared to its 5-year average forward P/E of 23.60. For a more detailed relative valuation and DCF analysis to assess Harmony Biosciences Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

23.60

Current PE

10.34

Overvalued PE

46.91

Undervalued PE

0.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.35

Current EV/EBITDA

5.21

Overvalued EV/EBITDA

20.43

Undervalued EV/EBITDA

4.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.51

Current PS

2.16

Overvalued PS

6.71

Undervalued PS

2.31

Financials

Annual

Quarterly

FY2025Q2

YoY :

+16.01%

200.49M

Total Revenue

FY2025Q2

YoY :

+25.30%

48.18M

Operating Profit

FY2025Q2

YoY :

+243.16%

39.78M

Net Income after Tax

FY2025Q2

YoY :

+240.00%

0.68

EPS - Diluted

FY2025Q2

YoY :

+88.93%

79.32M

Free Cash Flow

FY2025Q2

YoY :

-0.53%

80.97

Gross Profit Margin - %

FY2025Q2

YoY :

+3.27%

33.49

FCF Margin - %

FY2025Q2

YoY :

+195.68%

19.84

Net Margin - %

FY2025Q2

YoY :

+19.31%

23.17

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

386.5K

USD

6-9

Months

4.2M

USD

0-12

Months

141.7M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 18208.08% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

1.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

386.5K

USD

6-9

Months

4.2M

USD

0-12

Months

141.7M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HRMY News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

08:16:15

Harmony Biosciences backs FY25 revenue view $820M-$860M, consensus $843.63M

2025-08-05

08:14:46

Harmony Biosciences reports Q2 adjusted EPS 92c, consensus 96c

2025-06-11 (ET)

2025-06-11

08:13:20

Harmony Biosciences presents preclinical data for BP1.15205

News

4.0

08-07NASDAQ.COM

Validea Joel Greenblatt Strategy Daily Upgrade Report - 8/7/2025

4.0

08-06TipRanks

3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts

9.5

08-05Newsfilter

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025